Skip to content

Released Mar 31, 2025, during market hours

10-K filed Apr 1, 2025, 91 days after period end · 0000868278-25-000003

Q4 2024 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$1.49Mderivedno prior Q4 2023 on file+5.5% vs Q3 2024
Net Income-$34.36MderivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived-$150,000N/M
Operating Incomederived-$17,290,000N/M
Operating Cash Flowderived-$3,518,000N/M
Free Cash Flowderived-$3,558,000N/M
Margins · derived
Gross margin-10.0%
Operating margin-1157.3%
Net margin-2299.8%

What the release said

The release

Same quarter

MetricQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figures
Revenue$1.49M—$21.82M$45.16M
Net Income-$34.36M-$8.75M-$2.45M$10.59M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ProPhase Labs, Inc. · CIK 868278 · Engraved from SEC EDGAR